FDA OKs new John­son & John­son treat­ment for pso­ri­a­sis

Kuwait Times - - HEALTH & SCIENCE -

NEW BRUNSWICK, New Jersy: Peo­ple with the skin dis­or­der pso­ri­a­sis will have an­other treat­ment op­tion af­ter US reg­u­la­tors ap­proved a new drug from John­son & John­son. The Food and Drug Ad­min­is­tra­tion ap­proved Trem­fya (trehm-FEYE-eh) Thurs­day for peo­ple with mod­er­ate to se­vere plaque pso­ri­a­sis.

John­son & John­son said that in one pa­tient study about seven in 10 pa­tients get­ting Trem­fya had clear or nearly clear skin af­ter 24 weeks of treat­ment, com­pared with about four in 10 pa­tients re­ceiv­ing ri­val Ab­bVie’s Hu­mira, the world’s top sell­ing drug. Trem­fya, which is in­jected ev­ery eight weeks, can cause in­fec­tions and other se­ri­ous side ef­fects. It will cost $9,684 per dose, or about $58,100 per year, with­out in­sur­ance.—AP

NEW BRUNSWICK: This photo pro­vided by Janssen Biotech, Inc shows the drug Trem­fya.—AP

Newspapers in English

Newspapers from Kuwait

© PressReader. All rights reserved.